HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis.

AbstractPURPOSE:
The inhibitor of apoptosis proteins (IAP) are overexpressed in hormone-refractory prostate cancer, rendering the cancer cells resistant to radiation. This study aims to investigate the radiosensitizing effect of small-molecule IAP inhibitor both in vitro and in vivo in androgen-independent prostate cancer and the possible mechanism of radiosensitization.
EXPERIMENTAL DESIGN:
Radiosensitization of SH-130 in human prostate cancer DU-145 cells was determined by clonogenic survival assay. Combination effect of SH-130 and ionizing radiation was evaluated by apoptosis assays. Pull-down and immunoprecipitation assays were employed to investigate the interaction between SH-130 and IAPs. DU-145 xenografts in nude mice were treated with SH-130, radiation, or combination, and tumor suppression effect was determined by caliper measurement or bioluminescence imaging. Nuclear factor-kappaB activation was detected by luciferase reporter assay and quantitative real-time PCR.
RESULTS:
SH-130 potently enhanced radiation-induced caspase activation and apoptosis in DU-145 cells. Both X-linked IAP and cIAP-1 can be pulled down by SH-130 but not by inactive SH-123. Moreover, SH-130 interrupted interaction between X-linked IAP/cIAP-1 and Smac. In a nude mouse xenograft model, SH-130 potently sensitized the DU-145 tumors to X-ray radiation without increasing systemic toxicity. The combination therapy suppressed tumor growth more significantly than either treatment alone, with over 80% of complete tumor regression. Furthermore, SH-130 partially blocked tumor necrosis factor-alpha- and radiation-induced nuclear factor-kappaB activation in DU-145 cells.
CONCLUSIONS:
Our results show that small-molecule inhibitors of IAPs can overcome apoptosis resistance and radiosensitize human prostate cancer with high levels of IAPs. Molecular modulation of IAPs may improve the outcome of prostate cancer radiotherapy.
AuthorsYao Dai, Meilan Liu, Wenhua Tang, Jeffrey DeSano, Ezra Burstein, Mary Davis, Kenneth Pienta, Theodore Lawrence, Liang Xu
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 14 Issue 23 Pg. 7701-10 (Dec 01 2008) ISSN: 1078-0432 [Print] United States
PMID19047096 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Inhibitor of Apoptosis Proteins
  • NF-kappa B
  • Oligopeptides
  • Radiation-Sensitizing Agents
  • SH-130
Topics
  • Animals
  • Apoptosis (drug effects, radiation effects)
  • Blotting, Western
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunoprecipitation
  • Inhibitor of Apoptosis Proteins (antagonists & inhibitors, drug effects, metabolism)
  • Male
  • Mice
  • NF-kappa B (drug effects, radiation effects)
  • Oligopeptides (pharmacology)
  • Prostatic Neoplasms (therapy)
  • Radiation-Sensitizing Agents (pharmacology)
  • Radiotherapy
  • Reverse Transcriptase Polymerase Chain Reaction
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: